Nicholas Boyd-Gibbins, MEng, PhD
@nboydgibbins
UCL | Kyoto Univ. | CSO | cell engineering, cell therapy, immunotherapy, autoimmune, long COVID, iPSCs, cancer, genetics and neuroscience
@amaticahealth
ID: 594682448
30-05-2012 15:37:00
1,1K Tweet
2,2K Followers
638 Following
Excited to be separating subgroups of LC and MECFS patients in collab with Jack | amatica health In this case I am an outlier in the more “normal” metabolic group (label No 34 on the left) However, that group has markers higher for neuro- and chronic inflammation Amatica Health